Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients With Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up of the Pivotal Zuma-1 Trial
Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2017.12.644
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2018
Authors
Publisher
Elsevier BV